Vericiguat Modulates Osteoclast Differentiation and Bone Resorption via a Balance between VASP and NF-κB Pathways

Figure 5

Vericiguat dually regulated RANKL-triggered activation of IκB-α/NF-κB signaling pathway. (a, b) Western blot results of the expression of osteoclast-related signaling pathways (NF-κB, AKT, and MAPK) with or without RANKL stimulation (). indicated a comparison with the control group without RANKL. (c, d) Western blot results of the expression of IκB-α and NF-κB in BMMs after treatment with RANKL (50 ng/ml) for 30 min followed by Vericiguat with indicated concentrations. (e) Immunofluorescence staining of RANKL-induced P65 nuclear translocation with or without Vericiguat with indicated concentrations. (f, g) Western Blot and quantified results of MAPK and AKT in BMMs after treatment with RANKL (50 ng/ml) for 30 min followed by Vericiguat with indicated concentrations. means three independent experiments. indicated a comparison with the control group (Vericiguat, 0 nM): , , , and . ns: not statistically significant. .

(a)

(b)

(c)

(d)

(e)

(f)

(g)